PTC Therapeutics has abandoned its latest attempt to secure FDA approval for Duchenne muscular dystrophy (DMD) treatment Translarna, after the FDA said it was unlikely to approve the drug based on the ...
Novartis has made a dramatic return to the Huntington's disease therapy stage by licensing a candidate from PTC Therapeutics for a whopping $1 billion upfront. The deal – which has a potential total ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Brent Lang is the Executive Editor of Variety, covering the major Hollywood studios, as well as their corporate parents. He joined Variety in 2014. He was previously a senior reporter at TheWrap.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results